Patent · US Active

CD80 and CD86 binding protein compositions and uses thereof

US11261233B2 · kind B2 · utility

1Cited by

1References

19Claims

0Family size

Assignees

OncoC4, Inc. · US
CHILDREN'S NATIONAL MEDICAL CENTER · US

Inventors

Yang Liu · Columbus, US
Pan Zheng · Ann Arbor, US
Martin Devenport · Gaithersburg, US
Wei Wu · Washington, US
Xuexiang Du · Baltimore, US
Mingyue Liu · Shanghai, CN
Fei Tang · Washington, US

Key dates

Filing date	Sep 19, 2017
Grant date	Mar 1, 2022
Priority date	—
Expiry date	Aug 20, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.